All News
Filter News
Found 808,906 articles
-
Predicting Long COVID at Initial Point of COVID-19 Diagnosis: Institute for Systems Biology-Led Study Finds Several Warning Factors
1/25/2022
A significant portion of people who contract the SARS-CoV-2 virus – some estimates suggest more than 40 percent – suffer chronic effects known as Post Acute Sequelae of COVID-19 (PASC), commonly referred to as long COVID.
-
Melzi Surgical Appoints Financial Industry Executive, Michael Layman to Board of Directors
1/25/2022
Melzi Surgical announced today the appointment of Michael Layman to its Board of Directors.
-
New Study Validates Benefits of Convalescent Plasma for Some COVID-19 Patients
1/25/2022
Transfusions of blood plasma donated by people who have already recovered from infection with the pandemic virus may help other patients hospitalized with COVID-19, a new international study shows.
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
1/25/2022
Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab) as reported by Johnson & Johnson were USD 6,023 million in 2021.
-
ADDF and AFTD Partner to Support Wave Life Sciences' FTD and ALS Clinical Program
1/25/2022
The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) announced today that they have partnered to support Wave Life Sciences' FOCUS-C9 Phase 1b/2a clinical trial investigating WVE-004 as a potential treatment for C9orf72-associated frontotemporal degeneration (C9-FTD), as well as amyotrophic lateral sclerosis (C9-ALS).
-
Matinas BioPharma Provides Business Update and 2022 Strategic Outlook
1/25/2022
Matinas BioPharma Holdings, Inc. today is providing a business update on each of its ongoing programs and discussing its strategic outlook for 2022.
-
Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
1/25/2022
Athira Pharma, Inc. today announced that patient dosing has begun in SHAPE, a Phase 2 clinical trial of ATH-1017 for the treatment of Parkinson's disease dementia and Dementia with Lewy bodies. ATH-1017 is a small molecule designed to enhance the activity of Hepatocyte Growth Factor (HGF).
-
Defymed receives approval to start its pilot clinical study with ExOlin®: the promise of a physiological treatment for diabetic patients
1/25/2022
The French authorities validate the start of the therapeutic trial to evaluate the safety of the ExOlin® device for patients suffering from poorly controlled type 1 diabetes with severe glycaemic fluctuations and prone to severe hypoglycaemia.
-
Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)
1/25/2022
Imara Inc. today announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for tovinontrine (IMR-687).
-
Bone Solutions Launches Mg OSTEOINJECT Injectable Magnesium-Based Bone Void Filler
1/25/2022
Bone Solutions Inc. (BSI), an orthobiologics technology company located in Colleyville, Texas, announced today the immediate commercial launch of Mg OSTEOINJECT, the first injectable bone void filler in the U.S. to incorporate magnesium - a critical component for bone health and development.
-
Bay Area Lyme Foundation Funds $8M in Tick-borne Disease Research During the PandemicFoundation Embraces National Focus on Infectious Diseases as Education Tool
1/25/2022
Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, today announced that the organization has raised more than $8 million since the beginning of the pandemic of which 100% will be used directly for research and education programs focused on achieving its mission of making Lyme disease easy to diagnose and simple to cure.
-
SIGA Announces Preclinical Oncology Research Collaboration with BioarchitechInvestigating TPOXX® in Combination with Bioarchitech’s Oncolytic Vaccinia Immunotherapy Platform
1/25/2022
SIGA Technologies, Inc. today announced that it entered into a collaboration with Bioarchitech, a United Kingdom-based biotech company developing immunotherapy for the treatment of cancer.
-
New Study Shows Males Can Naturally Increase Sperm Count By 167%, Semen Volume by 53% and Testosterone Levels by 17%
1/25/2022
Cedars-Sinai Cardiologist Dr. David Filsoof has recently created a huge buzz in the medical community by sharing some extremely promising clinical studies for men that suffer from low testosterone and/or low fertility levels.
-
Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders
1/25/2022
Monte Rosa Therapeutics, Inc. announced a license and research collaboration agreement with Dr. Nir London and the Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science, which aims to accelerate the discovery and development of novel covalent molecular glue degraders leveraging CoLDR.
-
Millennia welcomes Ankit Sharma as its new Chief Data and Analytics Officer
1/25/2022
Millennia (the "Company"), a leader in patient payment and patient engagement for hospitals, health systems and medical groups, is excited to announce the addition of Ankit Sharma to its leadership team as the Chief Data and Analytics Officer.
-
Arcus Biosciences Announces New Employment Inducement Grants - Jan 25, 2022
1/25/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 38,850 shares of the Company’s common stock at an exercise price per share of $31.75, which was the closing price on January 24, 2022, and restricted stock units to acquire a total of 925 shares of the Company’s common stock.
-
Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
1/25/2022
Checkpoint Therapeutics, Inc. today announced positive topline results from its registration-enabling clinical trial evaluating the safety and efficacy of its anti-PD-L1 antibody.
-
AIROS Medical and Fist Assist Devices, LLC Announce Launch of Commercial Website for Fist Assist FA-1 Wearable Medical Device
1/25/2022
AIROS Medical, Inc., a designer, manufacturer, and distributor of compression therapy devices, and Fist Assist Devices, LLC (Fist Assist), an innovative medical device company, today announced the launch of an e-commerce website, www.fistassistusa.com, for the sale of the Fist Assist FA-1 compression device.
-
BD Board Declares Dividend - Jan 25, 2022
1/25/2022
The Board of Directors of BD has declared a quarterly dividend of $0.87 per common share, payable on March 31, 2022 to holders of record on March 10, 2022.
-
Summit Therapeutics Announces Rights Offering
1/25/2022
Summit Therapeutics Inc. today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the Company’s common stock, par value $0.01 (the “Common Stock”) as of the close of the market on February 4, 2022 (the “Record Date”).